Work

Subgroup Analysis of First–Year Results of ANCHOR: A Phase III, Double–Masked, Randomized Comparison of Ranibizumab and Verteporfin Photodynamic Therapy for Predominantly Classic Choroidal Neovascularization Related to Age–Related Macular Degeneration